

Bioxyme

Q2 FY2026

Presentation of Second Quarter Results

ASX:BXN

January 2026

Disclaimer



This presentation (Presentation) has been prepared by Bioxyne Limited ABN 97 084 464 193 (Bioxyne or the Company).

The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. The information in this presentation is subject to change without notice and, subject only to any legal obligations to do so, Bioxyne does not have any obligation to correct or update the contents of this Presentation.

The Presentation contains certain "forward-looking statements". The words "forecast", "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice and involve known and unknown risks and certainties and other factors which are beyond the control of Bioxyne, and its directors and management, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. This includes statements about market and industry trends, which are based on interpretations of current market conditions.

Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. Recipients are cautioned not to place undue reliance on forward-looking statements. Refer to the risk factors section of this Presentation for some of the key known risks. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this Presentation.

The forward-looking statements are based on information available to Bioxyne as at the date of this Presentation. Circumstances may change and the contents of this Presentation may become outdated as a result. Except as required by law or regulation, none of Bioxyne, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.

No party other than Bioxyne has authorised or caused the issue, lodgement, submission, dispatch or provision at the end of this Presentation, or takes any responsibility for, or makes or purports to make any statements, representations or undertakings in this Presentation. To the maximum extent permitted by law, Bioxyne (including its subsidiaries, related bodies corporate, shareholders, affiliates, advisers and agents):

- disclaims all responsibility and liability (including, without limitation, any liability arising from fault, negligence or negligent misstatement) for any loss arising from this Presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this Presentation;
- disclaims any obligations or undertaking to release any updates or revision to the information in this Presentation to reflect any change in expectations or assumptions; and
- does not make any representation or warranty, express or implied, as to the accuracy, reliability or completeness of the information in this Presentation or the likelihood of fulfilment of any forward-looking statement or any event or results expressed or implied in any forward-looking statement.

Not An Offer

This Presentation is not a prospectus, product disclosure document or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation is for information purposes only and should not be considered as, an offer, solicitation, inducement, recommendation or an invitation to acquire securities in Bioxyne or any other financial products, and neither this document nor any of its contents will form the basis of any contract or commitment.

This Presentation may not be distributed to any person in any country outside Australia except to the extent permitted under applicable laws. The release, publication or distribution of this Presentation (including an electronic copy) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions and should seek your own advice on such restrictions. Any non-compliance with these restrictions may contravene applicable securities laws.

Not Financial Product Advice

This Presentation is not financial product, investment advice or a recommendation to acquire Bioxyne securities and has been prepared without taking into account the objectives, financial situation or needs of individuals. Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation including, but not limited to, the assumptions, uncertainty and contingencies which may affect future operations of Bioxyne and the impact that different future outcomes may have on Bioxyne. Before making an investment decision prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Bioxyne is not licensed to provide financial product advice in respect of its securities or any other financial products.

This announcement has been approved by the Board.

Redefining Medicine

Cannabis | Psilocybin | MDMA

World's Fastest Growing Pharmaceutical Manufacturer


for patients with unmet clinical needs

What we do



Bioxyne is a **multinational pharmaceutical manufacturer** and healthcare company.

Wholly owned subsidiary **Breathe Life Sciences** is becoming a global market-leading distributor of controlled drugs, active pharmaceutical ingredients, and final dose form medicines derived from **cannabis, MDMA, Psilocybin**. The company also has a portfolio of branded prescription medicine and consumer health products (CBD, functional mushrooms, other) under its Dr Watson® brand, sold in Australia, Europe, UK, Japan, and USA.



Breathe Life Sciences (BLS)

Contract Drug Manufacturer, White label medicines manufacturer, wholesale distributor and GMP certified pharmaceutical manufacturing services provider in Australia, UK, Europe. AND consumer health products, novel foods, probiotics.

Dr Watson®

Offers branded health and prescription products, made by BLS sold in Australia, the UK, Germany, and Japan.

Research & Development

Focuses on new formulations and manufacturing processes, including patented probiotic capsules, MDMA and psilocybin products for clinical use, and efficiency improvements across operations.

Q2FY26 Overview - Another Record Quarter



Record **\$17.2m** Revenue
+21% QoQ
+112% on PcP



Record **\$18.4m** Cash Receipts



\$2.5m Positive Cash Flow from Operations
\$0.7m Capex



\$7.6m Cash on Hand
Inc. \$1.6m non-dilutive loan/grant funding from Scottish Gov.



Entry into New Markets:
UK, Germany, LATAM with significant growth potential.



Contract wins with significant clients including Curaleaf, Remidose, Adrex and more



First Australian-made GMP MDMA capsules & GMP Psilocybin capsules



Integration of Oracle NetSuite ERP system commenced January 2026

Sustained Growth +112% LTM



Key drivers of growth

- Expanded Australian manufacturing capacity
- Strong increase in white-label and branded product sales
- Successful entry into Germany and UK markets
- Significant contribution from export orders
- Emerging revenue from psychedelics segment
- Early supplies of GMP-compliant MDMA capsules


BXN REVENUE BY QUARTER (\$m)



Cash Flow Positive & \$7.6m Cash on Hand



CASH RECEIPTS & NET CASH USED IN OPERATING ACTIVITIES (\$m)



Record cash receipts of \$18.4 million

149% increase vs prior corresponding period (PCP) and 43% up on prior quarter (QoQ)

Positive operating cash flow of \$2.5 million in Q2 FY26

Driven by higher operational performance
Supported by \$1.1 million R&D tax offset

Strategic investment in working capital

Inventory increased to **\$11.5m** from **\$6.1m** in Q1 FY26 to support strong forecast demand in 2H FY26

Strong cash position

Cash on hand \$7.6m at end of Q2



Operational & Strategic Wins



NEW PARTNERSHIPS DRIVING GROWTH

- Exclusive Manufacturing Agreement for Curaleaf QMID medical device.
- Remidose agreement for THC pastilles in Costa Rica & Panama; (first-mover and ~A\$1 million potential revenue p.a.)

FAST-MOVING IN EUROPE'S FASTEST-GROWING MARKETS

- Secured £850k (~A\$1.6M) government funding for new UK GMP facility in Scottish Borders
- Mirroring Australia's scale to capture UK demand (2nd-largest EU cannabis market, fastest growing)

LEADING INNOVATOR IN MEDICAL CANNABIS & PSYCHEDELICS

- Delivered first Australian-made GMP MDMA capsules for PTSD trials
- 2 standing orders fulfilled Nov 2025
- Positioning for \$10B+ global psychedelics boom by 2030.

BUILDING GLOBAL BRAND EQUITY

- Frankfurt dual listing (PR8.F, 13 Oct 2025) to enhance Europe liquidity
- Dr Watson® branded products now available in Australia, UK, Germany with both prescription medicines and consumer health products.

FINANCIAL STRENGTH & FISCAL PRUDENCE

- FY26 guidance \$65M–75M revenue, \$11.5M–13.5M EBITDA
- Cash Flow Positive Full year FY26
- Strong balance sheet with growing net assets and minimal debt

DELOITTE TECH FAST 50 AWARD WINNER #14

- Bioxyne is in the top 15 fastest growing Australian Tech Companies in 2025 as recognized by Deloitte.

Corporate Structure




| CAPITAL STRUCTURE | |
|-----------------------|----------|
| Share price | \$0.039 |
| Market capitalisation | \$86.79m |
| 52-week high | \$0.060 |
| 52-week low | \$0.019 |

| FY26 GUIDANCE | |
|---------------|-------------------|
| Revenue | \$65m to \$75m |
| EBITDA | \$11.5 to \$13.5m |



BXN Share Price Performance – 12 Months (Jul 2024 – Jan 2026)



All data as of Jan2026